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The effects of the etyl acetate extract of root of Pachyrhizus 
erosus (L) Urb (EPE) on bone loss and in ovariectomized (ovx) 
rats model of osteoporosis were investigated. Forty-two 6-weeks-
old female Sprague–Dawley rats were randomly assigned to six 
groups as followed, sham-operated, OVX, OVX-Estradiol (2 
μg/day), OVX-EPE 200 mg/kg BW, OVX-EPE 400 mg/kg BW, 
OVX-EPE 800 mg/kg BW for 4 weeks. The administration of 
EPE was given orally using a stomach tube. The results 
demonstrated that the administration EPE 200, 400, and 800 
mg/kg BW significantly prevented bone loss in OVX rats which 
these effect equivalent to estradiol. These effects were described 
in increased length of femur and tibiae, bone density, and mineral 
content of calcium and phosphorous in bone ash. EPE also 
significantly prevented OVX-induced uterine atrophy and 
increased in body weight gain. The femur mechanical testing 
significantly increased the ultimate load and stiffness of femurs of 
ovariectomized-rats that its effect was greater than OVX or sham-
operated rats. Increased bone density may lead to enhanced bone 
strength, reducing the risk of fracture, which is evident in the 
administration of EPE due to high content of mineral density and 
content and increase the ultimate load. This effect seems to be 
pro-estrogenic compound, which suppress bone resorption by 
directly acting on estrogen receptor in bone sites. This study 
suggest that phytoestrogen compound from Pachyrhizus erosus 
may offer a potential alternative therapy for the treatment of 
health problems such as osteoporosis in post-menopausal women. 
 
Keywords: phytoestrogen, Pachyrhizus erosus, ovariectomized-
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Introduction 
Osteoporosis is one of the major health problem, 
and expected to increase dramatically in the 
recent decades. National Osteoporosis 
Foundation reported that about 44 million 
Americans are at risk of osteoporosis by having 
low bone mineral contents and densities. Ten 
million among these adult patients have 
osteoporosis and the majority of these patients are 
women. Recent epidemiological studies have 
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suggested that the incidence of osteoporosis is a 
complex interaction due to many factors such as 
variety of genetic, geographic, and ethnic factors 
[1-3].  Estrogen deficiency is generally not one of 
the major of the main risk factors for 
osteoporosis, but it is indirect and strongly related 
with the many recognized osteoporosis risk 
factors especially in women such as thin, 
advanced age, postmenopausal, amenorrhea, and 
more drinking alcohol. 
Several line of evidence reported the importance 
of estrogen in bone remodeling and metabolism. 
Furthermore, the evident from the clinical used 
that the administration of hormone replacement 
therapy (HRT) in a dose dependent manner 
effectively prevents bone loss in postmenopausal 
women [4,5] and reduces the incidence of 
osteoporosis [6-9]. Unfortunately, the use of HRT 
for long term caused several unwanted side effect 
associated with these powerful steroids and 
increased risk for breast and endometrial cancers 
[10,11]. Therefore, further exploration of 
alternatives and/or adjunctive approaches that can 
produce clinically relevant prevent bone loss like 
in osteoporosis would be interest. Non-hormonal 
theraphy or natural product therapy may more 





















Recently, much attention has been focused on 
phytoestrogens, especially isoflavones, as a 
potential safe alternative for pharmaceutical HRT 
[12]. Phytoestrogen is one of the natural 
alternatives that appear to offer the most potential 
for the prevent bone loss. Phytoestrogen is non-
steroid plant-derived compounds which 
structurally similar to estrogen and possesses 
both weak estrogenic and antiestrogenic effects 
[13,14]. Previous study in animals showed that 
phytoestrogen had a protective effect against 
bone loss due to estrogen deficiency. The 
consumption of natural phytoestrogen from 
soybean instead of a casein-based diet had been 
demonstrated to prevent bone loss in 
ovariectomized (OVX) rats [15,16]. Similarly, 
genistein, a phytoestrogen found predominantly 
in soybean, prevented bone loss in OVX rats [17-
19].  
Several line of evidences reported that estrogen 
receptors ERα and ERβ are presence in bone 
[20,21]. Both in vitro and in vivo studies have 
shown that daidzein, genistein, and their 
glycosides exert a weak estrogenic effect [22]. In 
addition, raloxifene  shown the positive effects of 
selective estrogen receptor modulators in animals 
[23] and humans [24]. Because of their similarity 



















Fig 1. Structure of phytoestrogen compounds from root of Pachyrhizus erosus (Lukitaningsih, 2009)  
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estrogen receptors [25], genistin have selective 
actions in bone [26,27]. Other studies 
demonstrated that human dietary studies shown 
the effects of isoflavone-rich soy protein diets on 
markers of bone turnover and preventing bone 
loss as measured from bone mineral density 
(BMD) and content [28,29]. Recent studies 
indicate that oral administration of daidzin, 
genistin, genistein and their succinyl derivatives 
significantly prevents bone loss in an ovx model 
of osteoporosis [18,30]. 
Pachyrhizus erosus (L) Urb or bengkoang is one 
of the natural plant contain some phytoestrogens. 
Many years, bengkoang root known and use for 
traditional cosmetic as sunscreen and whitening. 
At least  four phytoestrogen compounds have 
been isolated and identified at least 4 
phytoestrogen compounds in root of Pachyrhizus 
erosus (L) Urb such as daidzein, daidzein-7-O-β-
glucopyranose, (8,9)-furanyl-pterocarpan-3-ol, 
and 5-hydroxy-daidzein-7-O-β-glucopyranose 
(Fig.1) [31]. However, the estrogenic effect of 
phytoestrogen from Pachyrhizus erosus (L) Urb 
have not been investigated especially the novel 
compound, (8,9)-furanyl-pterocarpan-3-ol. 
Because of that, there is a great interest to 
investigate the effect and action of phytoestrogen 
of root of Pachyrhizus erosus (L) Urb on bone 
and uterine tissue in this osteoporosis model. 
 
Materials and Methods 
 
Plant and Chemical Materials 
Pachyrhizus erosus (L) Urb used in the present 
study were collected from commercial market 
and authenticated at the Laboratory of 
Pharmacognosy, Department of Pharmaceutical 
Biology, Gadjah Mada University, Yogyakarta, 
Indonesia. Ethanol 96%, methanol p.a, ethyl 
acetate p.a and petroleum ether p.a. were 
obtained from Sigma (St. Louis, MO, USA). 
Estradiol were purchased from Sigma (St. Louis, 




Preparation of Ethyl Acetate Extract of 
Pachyrhizus erosus (EPE) 
The dried powders of roots of Pachyrhizus erosus 
were extracted by soxhlet using petroleum ether 
in order to separate phytosterol. Further, the 
residue that obtained extracted again using 
methanol. The methanol extracts evaporated to 
obtain concentrated extract. This extract further 
dissolved in water and partition with ethyl 
acetate. Subsequently, the ethyl acetate fractions 
obtained were dried at 60°C on steam bath 
followed by a freeze dried to obtain dried extracts 
from Pachyrhizus erosus (EPE). The extractive 
value of ethyl acetate from dried powders was 




Figure 2. Effect of phytoestrogen of EPE on femoral mechanical 
strenght [ultimate load (A), Stiffness (B)] in ovariectomized 
(OVX)-rat model of osteoporosis. Each column represents mean 
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Animals 
Female Sprague–Dawley rats, aged 42 days, were 
purchased from Animal Laboratory Center Unit 
(The Laboratory of Research and Assessment, 
Gadjah Mada University, Yogyakarta, Indonesia). 
The animals were grouped and housed in 
polyacrylic cages with not more than five animals 
per cage and maintained under standard 
laboratory conditions (temperature 25 ± 2°C) 
with dark and light cycle (12/12 h) and allowed 
free access to commercial pellet diet (PT. 





Rats were acclimatized to laboratory condition 
for 1 week before commencement of experiment. 
All procedures described conducted in 
accordance with Guideline for Care and Use of 
Animals Laboratory of Faculty of Pharmacy, 
Gadjah Mada University. At 50 days of age, 
bilaterial ovariectomy was performed via a dorsal 
midline incision under ether anesthesia. Upon 
recovery from anesthesia, animals were assigned 
to experimental groups, normal (sham-operated), 
OVX, OVX-estradiol, OVX-EPE 200, OVX-EPE 
400, and OVX-EPE 800, with six to eight 
animals per group, per experiment. Twenty days 
after ovariectomy, all the rats were allowed 
controlled access to a commercial standard pellet 
and free access to deionized water for 20 days. 
Normal (sham-operated) and OVX rats were 
sacrified under light anesthesia to determine the 
baseline at 70 days. From 70 days, estradiol (2 
µg/day), EPE (200, 400 and 800 mg/kg BW/day) 
was given orally using a stomach tube for 4 
weeks. The food intake of all rats was measured 
every 3 d. At day 28 after first dosing, the urine 
of each rat was collected over 24 h, using a 
metabolic cage.  
 
On the day after the last dose, the rats were blood 
collected from orbital plexus after and sacrified 
under light anesthesia. The uterus was removed 
and the wet weight, was determined. The femurs 
and tibiae were also removed immediately for 
bone analyses. 
 
Serum and Urine Analysis 
Blood samples were centrifuged at 2000 × g for 
15 min to obtain serum, after standing for 30 min 
at room temperature. Serum Calcium and 
Phosphorus: Serum calcium and inorganic 
phosphate were measured 
spectrophotometrically, using commercial kits 
from DiaSys International (Holzheim, Germany). 
Urinary excretion of creatinine, calcium, and 
phosphorus were measured with a commercial kit 
from DiaSys International (Holzheim, Germany). 
  
Bone Length, Density and mineral content 
The femurs were also removed immediately after 
sacrified for bone analyses. The right and left 
femurs were freed of soft tissue. The removed 
right femurs were freed of soft tissue using small 
scissors, tweezers and cotton gauze. The length of 
each femur was measured with a Vernier caliper. 
Following the same method as in the previous 
report [30] bone volume and density were 
measured by applying Archimedes’ principle [32] 
Then the bones were dehydrated and defatted in 
acetone and anhydrous ether, dried for 12 h at 
110°C and reweighed to obtain the dry bone 
weights. Bone calcium and phosporus content in 
ash bone were determined by atomic absorbtion 
spectrophotometry (AAS). 
 
Femoral Mechanical Testing 
 
Bone Strength (Breaking Force) was measured 
according to Yao et al. (2005) [33] by means of a 
three-point bending test on an universal test 
instrument of the Instron type (Tokyo Testing 
Machine Mfg Co. Ltd., Tokyo, Japan), as 
reported previously. The three-point bending test 
was performed at a displacement rate of 0.05 
mm.min-1. The load-displacement curve was 
recorded simultaneously during the test. The 
ultimate load and the stiffness of the femoral 










Data from the animal experiments were 
expressed as the mean ± S.E.M. The statistical 
significance of differences between the groups 
were assessed with a one-way ANOVA, followed 
by Bonferroni or LSD post-hoc test analysis 
using rel 13.0 software SPSS (Chicago, IL, 
USA). p values of less than 0.05 were considered 





Body and Uterine Weights 
The effect of EPE on average body weight gain 
and uterus are presented in table 1. As decribed in 
table 1, ovariectomi caused atrophy of uterus 
(p<0.001). This effect was prevented by the 
administration of EPE 200 and 400 mg/kg BW, 
but not 800 mg/kg BW. In other hand, 
ovariectomy increased average daily body weight 
gain (p<0.001). This effect also was prevented by 
the administration of EPE 200, 400 and 800 
mg/Kg BW. The effect of EPE 800 mg/kg BW 
was greater than estradiol.  
 
Femoral Length, Density, and Calcium and 
Phosphorus Content 
 
The activities of EPE on bone were demonstrated in 
table 2. The result demonstrated that OVX caused 
bone loss which determined by decreased bone 
density (p<0.01), content of calcium bone (p< 0.05) 
and phosphorous (p<0.05) (Table. 2). The results 
shown that the administration of EPE 200, 400 and 
800 mg/kg BW for 28 days capable to increase the 
length of femur, tibiae, bone density and calcium 
content in bone (Table 2). These effect of all dose of 
EPE were greater than estradiol for length of femoral 
and tibiae. The effect of EPE 400 mg/kg BW on bone 
density was equivalent with estradiol. Furthermore, 
the administration of all doses of EPE and estradiol 
could restore the calcium content loss to the sham-
group, but only 400 mg/kg could restore to the sham-
group for phosphorous content loss and this effect was 
equivalent with estradiol. 
 
Table 1. Effect of phytoestrogen of EPE on body weight 



















2,62 ± 0,30 
0,199 ± 
0,041 












































Values are means±S.E.M., n=6−8 rats. Within a column, values 
with a superscript are significantly different: ## p,0.01, ### 
p,0.001 compared with sham rats; *p<0.05; **p<0.01; 
***p<0.001 compared with OVX rats. 
 
Table.2 Effect of phytoestrogen of EPE on femoral and 
tibiae lenght, bone density and bone mineral content in 






























33,09 ± 0,64 





















































31,55 ± 3,25 
Values are means±S.E.M., n=6−8 rats. Within a column, values 
with a superscript are significantly different: ## p<0.01, ### 
p<0.001 compared with sham rats; *p<0.05; **p<0.01; 




















Sham 20,91 ± 1,79 11,04 ± 1,79 605,84±190,83 
OVX 21,70 ± 2,63 11,60 ± 1,98 788,03±151,11 
Estradiol 14,78 ± 2,62* 19,36 ± 7,27* 364,68±102,21* 
OVX+EPE 
200 mg/kg 13,13 ± 1,94** 24,72 ± 9,72** 346,70±81,61* 
OVX+EPE 
400 mg/kg 14,57 ± 2,77* 15,42 ± 2,41* 404,22±73,99* 
OVX+EPE 
800 mg/kg 14,10 ± 2,88* 15,48 ± 2,59* 439,80±100,53* 
Table.3 Effect of phytoestrogen of EPE on serum calcium, phosphorus and alkaline 
phosphatase (ALP) in ovariectomized (OVX)-rat model of osteoporosis 
Values are means±S.E.M., n=6−8 rats. Within a column, values with a superscript are significantly different:  














Sham 100,00±64,23 15,87 ± 5,86 0,19 ± 0,09 233,64±61,11 3,08 ± 1,91 
OVX 106,00±45,19 14,89 ± 5,85 0,15 ± 0,04# 163,83±64,40# 1,65 ± 0,47# 
Estradiol 118,00±25,64* 8,47 ± 2,99* 0,07 ± 0,01*** 195,14±86,70 1,65 ± 0,90 
OVX+EPE 
200 mg/kg 119,00±64,56* 12,38 ± 11,09 0,09 ± 0,06** 136,20±122,00* 0,90 ± 0,62* 
OVX+EPE 
400 mg/kg 106,25±71,11 9,23 ± 6,26* 0,11 ± 0,06* 144,98±55,02* 1,95 ± 0,83 
OVX+EPE 
800 mg/kg 117,00±26,36* 10,54 ± 3,79 0,09 ± 0,02** 194,48±44,95* 1,67 ± 0,22 
Table 4. Effect of phytoestrogen of EPE on urinary calcium and phosphorus in ovariectomized (OVX)-rat 
model of osteoporosis 
Values are means±S.E.M., n=6−8 rats. Within a column, values with a superscript are significantly different: ## p<0.01 
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Femoral mechanical testing 
In OVX rats, ovariectomy slightly reduced 
ultimate load, an indicator of the material 
properties of bone, compared with sham rats (Fig. 
1). The results demonstrated that the 
administration of EPE 200, 400, and 800 mg/kg 
BW significantly increased the ultimate load and 
stiffness of femurs of ovariectomized-rats that its 
effect was greater than OVX or Sham (Fig 1 and 
2). EPE 400 mg/kg BW is the optimum dose to 
achieved greatest ultimate load and stiffness of 
femoral and its effect was equivalent to estradiol. 
 
Serum and Urinary Calcium and Phosphorus 
The effect of EPE on the mineral serum and 
urinary was presented in table 3. The 
administration of EPE 200, 400 and 800 mg/kg 
BW decreased the concentration of calcium in 
serum that indicated the bone formation. This 
effect is greater than estradiol (Table 3). 
Similarly, the clearance of urinary calcium 
decreased by the administration of EPE 200, 400, 
and 800 mg/kg BW and estradiol. The clearance 
of urinary phosphorus also decreased by 
administration of EPE 200, 400 mg/kg BW but 
not 800 mg/kg BW. 
 
Discussion 
The main objective of this study was to evaluate 
whether ethyl acetate extract of Pachyrhizus 
erosus (EPE) is effective in preventing bone loss 
due to ovariectomy and compare with estradiol. 
Ovariectomized rats are classically used as an 
animal model for studying the effect of 
postmenopausal bone loss [32]. Furthermore, 
they may provide a useful model for investigating 
the biological effect of EPE on bone loss in rat-
ovariectomized. Ethyl acetate extract from 
Pachyrhizus erosus at least contain isoflavone 
such as daidzein, daidzein-7-O-β-glucopyranose, 
5-hydroxy-daidzein-7-O-β-glucopyranose and 
(8,9)-furanyl-pterocarpan-3-ol [31]. Isoflavones 
daidzein in Pachyrhizus erosus form in conjugate 
or glycoside which are degraded by gut 
microflora, which influences their bioavailability. 
This enterohepatic cycle leads to a new 
circulation of daidzein in the blood circulation.  
Previous study shown that isoflavone genistin 
and daidzin  prevent bone loss in young 
ovariectomized rats [30]. Other study reported 
that daidzein more effective preventing bone loss 
in ovariectomy- induced bone loss in rats [19]. 
The present study was investigated the potential 
preventive effects of ethyl acetate exctract of  
Pachyrhizus erosus (EPE) which contain daizein 
or its glycoside and the novel compound, (8,9)-
furanyl-pterocarpan-3-ol on bone loss in animal 
model of osteoporosis. The administration of EPE 
prevented OVX-induced increase average body 
weight gain in rats. This results also support by 
previous study that daidzin prevented OVX-
induced uterine atrophy and increases in body 
weight gain, abdominal fat, serum total 
cholesterol and triglyceride [27]. In addition, 
other study also reported that soybeans-rich 
isoflavones dietary interventions effectively 
reduce cholesterol serum in OVX-induced 
increased cholesterol serum in rats [15]. 
According with previous report, rats in the OVX 
group had lower densities of the right femur and 
tibiae because of reducing the ovariectomy-
induced increase in bone resorption [15,19,32]. 
The administration of EPE 200, 400 and 800 
mg/kg BB effectively prevented OVX-induced 
lowering bone density and increased lenght of 
femure and tibiae. These observations are 
supported by previous study that isoflavones 
daidzin, genistin and glycitin significantly 
prevented bone loss in OVX rats, like estrone 
[27]. In addition, the result also demonstrated that 
the rats receiving EPE shown greater load strain 
than sham and OVX. Increased bone density may 
lead to enhanced bone strength, reducing the risk 
of fracture, which is evident in the administration 
of EPE due to high content of mineral density and 
content and increase the ultimate load. The 
preventive effect of EPE may be due to enhanced 
intestinal absorption. Although we did not assess 
intestinal calcium absorption in this study, the 
enhanced intestinal absorption of calcium along 
may be by the modulation of parathyroid 
hormone and renal function [34]. This finding 
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days increased the ovariectomy-induced rate of 
bone formation. Previous study proposed that 
daidzein act as proestrogenic compounds based 
on bone loss and uterine in OVX rats which that 
may be tissue-specific 27]. Both in vitro and in 
vivo studies have shown that daidzein, genistein, 
and their glycosides exert a weak estrogenic 
effect [22]. In fact, estrogen receptors are 
presence in bone [20,21]. In accord similarity of 
isoflavone content and structure, we propose that 
the mechanism of preventing bone loss in 
ovariectomy rats through the binding of its 
compounds in Pachyrhizus erosus (Fig.1) to 
estrogen receptor in bone. 
In summary, we have demonstrated that the 
administration of ethyl acetate extract from 
Pachyrhizus erosus prevents bone loss in an 
ovariectomy rat model of osteoporosis. This 
effect seems to be proestrogenic compound, 
which suppress bone resorption by directly acting 
on estrogen receptor in bone sites. Isolation and 
use of phytoestrogen compound from 
Pachyrhizus erosus may offer a potential 
alternative therapy for the treatment of health 
problems such as osteoporosis in post-
menopausal women. The mechanisms of 
phytoestrogen compounds of Pachyrhizus erosus 
on bone in OVX rats appear to be similar to that 
of estradiol. Further studies are needed to 
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